Literature DB >> 19655265

Immunohistochemical expression of dog TERT in canine testicular tumours in relation to PCNA, ki67 and p53 expression.

N Papaioannou1, D Psalla, M Zavlaris, P Loukopoulos, N Tziris, I Vlemmas.   

Abstract

The objective of the study was to determine the immunohistochemical expression of canine TERT in canine testicular tumours comparing two different antibodies for TERT, and to correlate them with well established markers specific to dividing cells such as PCNA and ki67, and with expression of the p53 tumour suppressor gene. The study included 36 cases of canine testicular tumours, which were categorized as 12 Sertoli Cell Tumours (SCT), 20 seminomas, 3 interstitial cell tumours and 1 mixed germ cell-sex cord stromal tumour (MT). Two antibodies for hTERT were examined; a highly specific TERT antibody, RCK-hTERT, was evaluated for the first time. Immunodetection of RCK-hTERT was observed in 31% of tumours examined (6/20 Seminomas, 4/12 SCT, 1/3 interstitial cell tumour and 0/1 mixed germ cell-sex cord stromal tumour), while the NCL-hTERT in 67% of them (15/20 Seminomas, 6/12 SCT, 3/3 interstitial cell tumour and 0/1 ΜΤ). PCNA immunoreactivity was detected in all cases. Regarding ki67, 3 SCT, 12 seminomas and all interstitial cell tumours showed clear immunoreaction. p53 immunoreactivity was detected in 6 SCT, 15 seminomas and all interstitial cell tumours. The immunohistochemical expression of both TERT antibodies are discussed and compared in order to clarify their potential usefulness in canine testicular malignancies in relation to the expression of well known cell cycle markers. Our results indicate that TERT and PCNA are useful proliferation markers but not helpful to evaluate prognosis. Instead of that ki67 and p53 could be used for predicting aggressiveness in this group of tumours.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19655265     DOI: 10.1007/s11259-009-9308-2

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


  62 in total

Review 1.  Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT).

Authors:  J C Poole; L G Andrews; T O Tollefsbol
Journal:  Gene       Date:  2001-05-16       Impact factor: 3.688

2.  Involvement of 14-3-3 proteins in nuclear localization of telomerase.

Authors:  H Seimiya; H Sawada; Y Muramatsu; M Shimizu; K Ohko; K Yamane; T Tsuruo
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

3.  Biological grading of breast cancer using antibodies to proliferating cells and other markers.

Authors:  S S Bacus; R Goldschmidt; D Chin; G Moran; D Weinberg; J W Bacus
Journal:  Am J Pathol       Date:  1989-11       Impact factor: 4.307

Review 4.  Clinical application of morphologic and immunocytochemical assessments of cell proliferation.

Authors:  M D Linden; F X Torres; J Kubus; R J Zarbo
Journal:  Am J Clin Pathol       Date:  1992-05       Impact factor: 2.493

5.  Assessment of proliferative activity by anti-PCNA monoclonal antibodies in formalin-fixed, paraffin-embedded samples and correlation with mitotic index.

Authors:  G Sarli; C Benazzi; R Preziosi; P S Marcato
Journal:  Vet Pathol       Date:  1995-01       Impact factor: 2.221

6.  Expression of p53 protein in spermatogenesis is confined to the tetraploid pachytene primary spermatocytes.

Authors:  D Schwartz; N Goldfinger; V Rotter
Journal:  Oncogene       Date:  1993-06       Impact factor: 9.867

7.  hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization.

Authors:  M Meyerson; C M Counter; E N Eaton; L W Ellisen; P Steiner; S D Caddle; L Ziaugra; R L Beijersbergen; M J Davidoff; Q Liu; S Bacchetti; D A Haber; R A Weinberg
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

8.  Immunohistochemical analysis of c-yes and c-erbB-2 oncogene products and p53 tumor suppressor protein in canine mammary tumors.

Authors:  A Rungsipipat; S Tateyama; R Yamaguchi; K Uchida; N Miyoshi; T Hayashi
Journal:  J Vet Med Sci       Date:  1999-01       Impact factor: 1.267

9.  Validation of the use of proliferation markers in canine neoplastic and non-neoplastic tissues: comparison of KI-67 and proliferating cell nuclear antigen (PCNA) expression versus in vivo bromodeoxyuridine labelling by immunohistochemistry.

Authors:  A Zacchetti; E van Garderen; E Teske; H Nederbragt; J H Dierendonck; G R Rutteman
Journal:  APMIS       Date:  2003-03       Impact factor: 3.205

10.  Increased expression of mutant forms of p53 oncogene in primary lung cancer.

Authors:  R Iggo; K Gatter; J Bartek; D Lane; A L Harris
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

View more
  2 in total

1.  Immunohistochemical detection of p53 and pp53 Ser392 in canine hemangiomas and hemangiosarcomas located in the skin.

Authors:  María José García-Iglesias; Jose Luis Cuevas-Higuera; Ana Bastida-Sáenz; María Gracia de Garnica-García; Laura Polledo; Paula Perero; Jorge González-Fernández; Beatriz Fernández-Martínez; Claudia Pérez-Martínez
Journal:  BMC Vet Res       Date:  2020-07-13       Impact factor: 2.741

2.  Fatal haemorrhage and neoplastic thrombosis in a captive African lion (Panthera leo) with metastatic testicular sex cord-stromal tumour.

Authors:  Omar Antonio Gonzales-Viera; Angélica María Sánchez-Sarmiento; Natália Coelho Couto de Azevedo Fernandes; Juliana Mariotti Guerra; Rodrigo Albergaria Ressio; José Luiz Catão-Dias
Journal:  Acta Vet Scand       Date:  2017-10-13       Impact factor: 1.695

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.